Literature DB >> 33764550

Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.

Jung Gil Park1,2, Jinho Jung1, Kritin K Verma1, Min Kyu Kang2, Egbert Madamba1, Scarlett Lopez1, Aed Qas Yonan1, Amy Liu1, Ricki Bettencourt1, Claude Sirlin3, Rohit Loomba1,4.   

Abstract

BACKGROUND: Magnetic resonance elastography (MRE) is a reliable non-invasive alternative to liver biopsy for assessing liver fibrosis. There are limited data regarding an association between liver fibrosis by MRE and risk of cardiovascular disease (CVD). AIM: To investigate the association of high-risk CVD phenotype determined by coronary artery calcification (CAC) with liver fibrosis by MRE in patients with non-alcoholic fatty liver disease (NAFLD).
METHOD: This was a cross-sectional analysis of well-characterised, prospective cohorts including 105 patients with NAFLD (MR imaging-derived proton density fat fraction ≥ 5%) with contemporaneous cardiac computed tomography (CT) and MRE. Patients were assessed using MRE for liver stiffness, and cardiac CT for the presence of CAC (defined as coronary artery calcium score > 0). Odds of presence of CAC were analysed using logistic regression analysis.
RESULTS: The average age and body mass index were 54.9 years and 32.9 kg/m2 respectively. In this cohort, 49.5% of patients had CAC and 35.2% had significant liver fibrosis (defined as MRE ≥2.97 kPa). Compared to patients without CAC, those with CAC were older (50.0 [39.0-59.0] vs 63.0 [55.5-67.5], P < 0.001) and had higher Framingham risk score (FRS, 1.0 [0.5-3.5] vs 6.0 [2.0-12.0], P < 0.001). In multivariable-adjusted analysis, liver stiffness as a continuous trait on MRE was independently associated with the presence of CAC in a sex and age-adjusted model (adjusted odd ratios [aOR] = 2.23, 95% confidence interval [CI] = 1.31-4.34, P = 0.007) as well as in a FRS-adjusted model (aOR = 2.16, 95% CI = 1.29-4.09, P = 0.008). When analysed as a dichotomous trait, significant fibrosis (MRE-stiffness ≥2.97 kPa) remained independently associated with the presence of CAC in both FRS-adjusted model and sex and age-adjusted model (aOR = 3.21-3.53, P = 0.013-0.017). In addition, CAC was more prevalent in patients with significant fibrosis than those without as determined by MRE (67.6% vs 39.7%, P = 0.012).
CONCLUSION: Liver stiffness determined by MRE is an independent predictor for the presence of CAC in patients with NAFLD. Patients with NAFLD and significant fibrosis by MRE should be considered for further cardiovascular risk assessment, regardless of their FRS.
© 2021 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 33764550      PMCID: PMC8514119          DOI: 10.1111/apt.16324

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  31 in total

1.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Authors:  Eduardo Vilar-Gomez; Luis Calzadilla-Bertot; Vincent Wai-Sun Wong; Marlen Castellanos; Rocio Aller-de la Fuente; Mayada Metwally; Mohammed Eslam; Licet Gonzalez-Fabian; María Alvarez-Quiñones Sanz; Antonio Felix Conde-Martin; Bastiaan De Boer; Duncan McLeod; Anthony Wing Hung Chan; Naga Chalasani; Jacob George; Leon A Adams; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2018-05-05       Impact factor: 22.682

2.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

Review 3.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Authors:  Leon A Adams; Quentin M Anstee; Herbert Tilg; Giovanni Targher
Journal:  Gut       Date:  2017-03-17       Impact factor: 23.059

4.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.

Authors:  Dong Hyun Sinn; Danbee Kang; Yoosoo Chang; Seungho Ryu; Seonhye Gu; Hyunkyoung Kim; Donghyeong Seong; Soo Jin Cho; Byoung-Kee Yi; Hyung-Doo Park; Seung Woon Paik; Young Bin Song; Mariana Lazo; Joao A C Lima; Eliseo Guallar; Juhee Cho; Geum-Youn Gwak
Journal:  Gut       Date:  2016-09-06       Impact factor: 23.059

6.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

7.  Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.

Authors:  Jacqueline B Henson; Tracey G Simon; Alyson Kaplan; Stephanie Osganian; Ricard Masia; Kathleen E Corey
Journal:  Aliment Pharmacol Ther       Date:  2020-02-11       Impact factor: 8.171

Review 8.  Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Laurent Castera; Mireen Friedrich-Rust; Rohit Loomba
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

9.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

Authors:  Giovanni Targher; Christopher D Byrne; Amedeo Lonardo; Giacomo Zoppini; Corrado Barbui
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

10.  Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver.

Authors:  Toshihiro Niikura; Kento Imajo; Anna Ozaki; Takashi Kobayashi; Michihiro Iwaki; Yasushi Honda; Takaomi Kessoku; Yuji Ogawa; Masato Yoneda; Hiroyuki Kirikoshi; Satoru Saito; Atsushi Nakajima
Journal:  Diagnostics (Basel)       Date:  2020-02-26
View more
  4 in total

Review 1.  Magnetic resonance elastography: from invention to standard of care.

Authors:  Richard L Ehman
Journal:  Abdom Radiol (NY)       Date:  2022-07-19

2.  Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.

Authors:  Thierry Thévenot; Sophie Vendeville; Delphine Weil; Linda Akkouche; Paul Calame; Clémence M Canivet; Claire Vanlemmens; Carine Richou; Jean-Paul Cervoni; Marie-France Seronde; Vincent Di Martino; Jérôme Boursier
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

3.  Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis.

Authors:  George Koulaouzidis; Dafni Charisopoulou; Michał Kukla; Wojciech Marlicz; Grażyna Rydzewska; Anastasios Koulaouzidis; Karolina Skonieczna-Żydecka
Journal:  Prz Gastroenterol       Date:  2021-09-17

Review 4.  Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.

Authors:  Jorge Gutiérrez-Cuevas; Arturo Santos; Juan Armendariz-Borunda
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.